Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)
Close on Nov 13, 2026Market cap $2.36BP/E –Yield –
Beam Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Beam Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -242.3%. For fiscal 2025 it was -274.6%, against -654.3% the year before. The highest annual figure on record is -46.7% in fiscal 2023.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -274.6% | +379.7 |
| FY2024 | Dec 31, 2024 | -654.3% | −607.5 |
| FY2023 | Dec 31, 2023 | -46.7% | +508.9 |
| FY2022 | Dec 31, 2022 | -555.6% | +201.4 |
| FY2021 | Dec 31, 2021 | -757.0% | +552409.7 |
| FY2020 | Dec 31, 2020 | -553166.7% | −135644.4 |
| FY2019 | Dec 31, 2019 | -417522.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -25827.1% | −24407.9 |
| Q1 FY2026 | Mar 31, 2026 | -337.8% | +1259.1 |
| Q4 FY2025 | Dec 31, 2025 | -15.3% | +317.4 |
| Q3 FY2025 | Sep 30, 2025 | -1307.6% | −561.2 |
| Q2 FY2025 | Jun 30, 2025 | -1419.2% | −528.2 |
| Q1 FY2025 | Mar 31, 2025 | -1596.9% | −191.6 |
| Q4 FY2024 | Dec 31, 2024 | -332.7% | −374.7 |
| Q3 FY2024 | Sep 30, 2024 | -746.4% | −116.7 |
| Q2 FY2024 | Jun 30, 2024 | -891.1% | −383.3 |
| Q1 FY2024 | Mar 31, 2024 | -1405.3% | −996.6 |
| Q4 FY2023 | Dec 31, 2023 | 42.0% | +486.1 |
| Q3 FY2023 | Sep 30, 2023 | -629.7% | −51.8 |
| Q2 FY2023 | Jun 30, 2023 | -507.8% | −15.6 |
| Q1 FY2023 | Mar 31, 2023 | -408.7% | +495.3 |
| Q4 FY2022 | Dec 31, 2022 | -444.1% | −319.8 |
| Q3 FY2022 | Sep 30, 2022 | -577.9% | +8548.4 |
| Q2 FY2022 | Jun 30, 2022 | -492.2% | +982407.8 |
| Q1 FY2022 | Mar 31, 2022 | -904.0% | +3338646.0 |
| Q4 FY2021 | Dec 31, 2021 | -124.3% | +679859.0 |
| Q3 FY2021 | Sep 30, 2021 | -9126.3% | +612890.3 |
| Q2 FY2021 | Jun 30, 2021 | -982900.0% | −544816.7 |
| Q1 FY2021 | Mar 31, 2021 | -3339550.0% | −2866966.7 |
| Q4 FY2020 | Dec 31, 2020 | -679983.3% | −240466.7 |
| Q3 FY2020 | Sep 30, 2020 | -622016.7% | −321616.7 |
| Q2 FY2020 | Jun 30, 2020 | -438083.3% | −143900.0 |
| Q1 FY2020 | Mar 31, 2020 | -472583.3% | – |
| Q4 FY2019 | Dec 31, 2019 | -439516.7% | – |
| Q3 FY2019 | Sep 30, 2019 | -300400.0% | – |
| Q2 FY2019 | Jun 30, 2019 | -294183.3% | – |
See a number that looks wrong?